Engineering oral commensal nanovaccines to activate mucosal-systemic immune cascades against tumor
Cell Host & Microbe · 2026
DOI: 10.1016/j.chom.2026.06.021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Host & Microbe, 2026. Verfasst von Zirong Dong und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, State Key Laboratory of Advanced D…. Hauptthemen laut MEDLINE: Nanovaccines, Cancer Vaccines, Immunity, Mucosal, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
Mucosal immunity-the body's frontline defense, harboring 80% of the body's immune cells-represents a potent yet underexploited avenue for cancer vaccination. Here, we developed an oral biohybrid vaccine platform by integrating tumor antigen-loaded liposomes with fimbriae-enriched bacteria (Escherichia coli or VNP20009) through bacterial hitchhiking or membrane hybridization. These biohybrids promote mucosal antigen delivery via glycoprotein 2 (GP2)-mediated microfold-cell (M-cell) transcytosis, enhancing antigen cross-presentation and activation of a mucosa-periphery-tumor immune cascade. Bacterial membrane-hybridized vaccines outperform bacteria-hitchhiking counterparts by reconfiguring dendritic cell (DC) subsets within gut-associated lymphoid tissues (GALTs) and triggering C-C chemokine receptor type 7 (CCR7)-dependent immune cell trafficking, thereby propagating mucosal immune activation toward distal tumor microenvironment (TME) reprogramming and tumor control. When combined with PD-1 blockade, this strategy enhances antitumor efficacy by promoting effector cell mobilization and establishing memory against tumor rechallenge. Collectively, these findings position bacteria-derived arsenal biohybrids as a versatile oral vaccine strategy, advancing mucosal immunotherapy for cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, State Key Laboratory of Advanced Drug Formulations for Overcoming Delivery Barriers, Shanghai 201203, Ch…
Förderung
- Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Dong, Z., Li, S., Wei, Y., Zhao, J., Kong, W., Liu, W., Chen, J., He, H., Yang, J., & Qi, J. (2026). Engineering oral commensal nanovaccines to activate mucosal-systemic immune cascades against tumor. Cell Host & Microbe. https://doi.org/10.1016/j.chom.2026.06.021
Vancouver
Dong Z, Li S, Wei Y, Zhao J, Kong W, Liu W, et al. Engineering oral commensal nanovaccines to activate mucosal-systemic immune cascades against tumor. Cell Host & Microbe. 2026. doi:10.1016/j.chom.2026.06.021
BibTeX
@article{Dong2026,
author = {Dong, Zirong and Li, Shuyan and Wei, Yuning and Zhao, Jiaxin and Kong, Weiwen and Liu, Wenjuan and Chen, Jian and He, Haisheng and Yang, Jinlong and Qi, Jianping},
title = {Engineering oral commensal nanovaccines to activate mucosal-systemic immune cascades against tumor},
journal = {Cell Host & Microbe},
year = {2026},
doi = {10.1016/j.chom.2026.06.021}
}
EUVIMED